ScripBiopharmaceutical company valuations overall still are down by double digits year-to-date, but as the second quarter transitioned into the third stock prices have begun to rise across the industry as
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Lilly/Avidity Partnership In